RNA干扰技术抑制Polo-like激酶1表达对A549细胞的影响

Polo-like激酶1(Plk1)是参与细胞周期调控的重要分子,已在多种肿瘤中检测到Plk1的高表达,并发现与肿瘤细胞的增殖和预后密切关联.为明确Plk1在肺癌细胞系A549细胞增殖和周期运行中的作用,采用RNA干扰技术,构建能产生siRNA的质粒载体psiRNA-hH1-Plk1并导入A549细胞中.采用RT-PCR检测Plk1mRNA表达的变化,Western印迹检测Plk1、细胞周期蛋白B1、p53蛋白的表达变化,流式细胞术分析细胞周期变化和凋亡;免疫荧光染色检测α微管蛋白的表达.以此观察RNA干扰能否有效抑制Plk1的表达水平,以及抑制后对A549细胞生长的影响.结果表明,psiRNA-hH1-Plk1质粒能特异性地抑制Plk1基因的表达并使其活性下降,细胞周期蛋白B1及p53蛋白的表达水平升高,微管聚集障碍或形成单极的纺锤体,A549细胞增殖减慢,出现G2/M期阻滞并存在细胞凋亡.针对Plk1基因的RNA干扰有望用于肿瘤的基因治疗.     

茅苍术提取物在肺癌A549细胞中的抗增殖作用机制

目的:研究茅苍术提取物对肺癌A549细胞的肿瘤增殖抑制效果及机制。方法:MTT比色法检测茅苍术提取物对A549细胞增殖的抑制效果;流式细胞术分析茅苍术提取物对肺癌A549细胞周期的影响;Western Blot检测茅苍术刺激前后细胞周期蛋白D1(cyclin D1)蛋白表达量变化。结果:茅苍术提取物能有效抑制肺癌A549细胞增殖,且抑制效果与茅苍术提取物浓度呈现依赖性,茅苍术提取物刺激48h后,抑制效果最佳,IC50约为77.12μg/ml;细胞周期分析显示:茅苍术提取物可将细胞周期阻滞在G0/G1期,50μg/ml茅苍术提取物刺激48h后,G1期上升至53.41%;cyclin D1蛋白含量因茅苍术作用而下调。结论:茅苍术提取物能通过有效抑制cyclin D1的表达,进而将细胞周期阻滞于G1期,最终实现其抗增殖作用机制。     

丙戊酸钠抑制A549细胞生长

目的研究丙戊酸钠对肺癌A549细胞增殖和细胞周期的影响。方法MTT检测生长抑制,流式细胞仪检测细胞周期和凋亡,Western blot检测p21WAF1/CIP1蛋白表达。结果丙戊酸钠以剂量依赖性方式抑制A549细胞生长;丙戊酸钠上调G0/G1期比例,下调S期和G2/M期,不影响细胞凋亡;丙戊酸钠上调p21WAF1/CIP1蛋白表达。结论丙戊酸钠上调p21WAF1/CIP1表达,使细胞阻滞于G0/G1期,抑制A549细胞生长。     

转录因子HBP1抑制骨肉瘤细胞增殖

转录因子HBP1(HMG-box containing protein 1, HBP1)属HMG家族,是1个含有513个氨基酸残基的多肽,可与RB蛋白结合,抑制许多癌基因的表达,从而抑制细胞的增殖. 本工作构建了HBP1慢病毒表达载体,病毒包装后感染骨肉瘤细胞U2OS细胞.Western印迹结果显示,感染细胞cyclin D1、c-Myc蛋白质水平降低 ,而p53蛋白质水平增加;Real-time PCR检测cyclin D1、c-Myc及p53 mRNA水平与蛋白质检测结果一致. HBP1表达载体（pEFBOS-HBP1）和报告基因载体（含 cyclin D1、c-Myc或p53 promoter）共转染U2OS细胞后的荧光素酶分析发现,HBP1可抑制cyclin D1、c-Myc启动子转录激活,促进p53启动子转录激活,并且这种抑制或激活作用具有HBP1剂量依赖性. 以细胞代龄群体倍增值PD （population doubling）为指标测试细胞生长结合软琼脂集落形成实验证明,HBP1慢病毒感染的U2OS细胞生长速度减缓、集落形成能力下降. 上述结果提示,HBP1可能通过调控细胞增殖相关基因的表达抑制骨肉瘤细胞的增殖.     

Napsin A基因对A549细胞在上皮-间质转化中增殖的影响及其机制

采用慢病毒载体质粒PLJM1将NapsinA基因转染到人肺腺癌细胞——A549细胞中,获得稳定表达Napsin A蛋白的特性并鉴定,通过转化生长因子-β1刺激A549细胞发生上皮-间质转化,体外构建上皮-间质转化模型并鉴定。MTT法检测转基因前后A549细胞在上皮-间质转化过程中生长速率的变化;流式细胞术检测其细胞周期的改变,最后予Western blot检测黏着斑激酶的表达情况,探讨Napsin A基因对A549细胞在上皮-间质转化过程中增殖的影响及其机制。结果表明转染后的A549细胞表达Napsin A蛋白明显增加(P<0.01);A549细胞发生上皮-间质转化后细胞E钙蛋白表达下调(P<0.01),Ⅰ型胶原表达上调(P<0.01);转基因细胞在体外上皮-间质转化模型中增殖速度减慢(P<0.05),且细胞周期被阻滞在G_1期(P<0.01),其表达整合素信号传导通路的基础分子——黏着斑激酶的量显著下降(P<0.01)。提示Napsin A基因可以抑制A549细胞在上皮-间质转化过程中的进一步增殖,其机制可能与抑制整合素信号传导通路有关。     

siRNA-cyclin D1对乳腺癌MCF-7细胞增殖的抑制作用

研究小干扰RNA(small interfering RNA,siRNA)对乳腺癌MCF-7细胞株cyclin D1表达的抑制及对细胞增殖的影响。化学合成针对cyclin D1基因的siRNA,转染MCF-7细胞株;分别应用荧光定量PCR和免疫印迹测定cyclin D1 mRNA和蛋白的表达,CCK-8测定细胞的增殖活性,流式细胞仪检测细胞周期,软琼脂培养检测细胞克隆形成能力。在实验中,10、50、100 nmol/L siRNA-cyclin D1分别使MCF-7细胞cyclin D1 mRNA表达降低了57．85%、63．22%和68．02%,蛋白表达降低了51．13%、62．09%、77．68%。转染siRNA-cyclin D1后,细胞增殖受到抑制,细胞周期阻滞于G1期,软琼脂克隆形成率降低。结果提示siRNA可以有效抑制MCF-7细胞株中cyclin D1的表达,使细胞周期阻滞于G1期,从而抑制细胞增殖。     

糖原合酶激酶3β以细胞周期蛋白D1依赖性方式引发人肺腺癌细胞A549细胞周期阻滞

对糖原合酶激酶3β（glycogen synthase kinase 3β,6SK3β）在细胞增殖中的作用研究,在不同细胞系和不同刺激因素作用下得出了不同结论,本文旨在探讨GSK3β在人肺腺癌细胞系A549细胞生长中的直接作用。A549细胞瞬时转染持续激活型S9A-GSK3β以及显性负突变型KM-GSK3β两种GSK3β突变型质粒,改变GSK3β活性。24 h后,分别进行细胞计数,流式细胞术及Western blot检测。结果显示,增强GSK3β活性可导致细胞数量下降,G．期细胞百分比升高。细胞周期蛋白D1表达水平被GSK3β下调。结果提示,GSK3β可能以细胞周期蛋白D1依赖性方式引发A549细胞的G,期阻滞,从而发挥生长抑制效应。     

曲古霉素A抑制肺癌细胞增殖的分子机制

目的:探讨组蛋白去乙酰化酶抑制剂曲古霉素A(trichostatin A,TSA)对人非小细胞肺癌(NSCLC)A549细胞增殖抑制作用及机制.方法:以不同剂量TSA(0.1μM,0.5pM和1μM)处理A549细胞.MTT法检测细胞增殖情况,碘化丙啶(PI)染色结合流式细胞仪检测细胞周期,Westem blot法检测P21蛋白表达,流式细胞仪检测细胞线粒体膜电位和细胞凋亡.结果:TSA剂量依赖性抑制肺癌A549细胞增殖,表现为细胞周期阻滞于G2/M期,同时P21蛋白表达增高;此外,TSA还可以剂量依赖性的促进A549细胞凋亡,伴有线粒体膜电位下降.结论:TSA促进NSCLCA549细胞周期阻滞和凋亡,从而抑制其增殖.     

马来酸罗格列酮对人肺腺癌（A549）细胞中PGC-1α表达及增殖的影响

摘要：为探讨马来酸罗格列酮对肺腺癌（A549）细胞中PGC-1a表达和活性的影响,以及抑制细胞增殖的机制,我们首先构建了pGL3-PGC-1a promoter重组质粒,转染人肺腺癌A549细胞,用双荧光素酶报告基因系统检测马来酸罗格列酮对PGC-1a启动子转录活性的影响;实时定量PCR检测胞内PGC-1a mRNA的表达;用Mitotracker green染色, 流式细胞仪检测线粒体质量;细胞计数检测马来酸罗格列酮对A549细胞体外增殖的影响。结果显示,马来酸罗格列酮能够抑制pGL3-PGC-1apromoter重组质粒的转录活性,降低A549细胞PGC-1amRNA水平的表达及线粒体质量,具有明显的剂量依赖性（P<0.05）。其抑制PGC-1a表达和活性的IC50（约为80 umol/L）与马来酸罗格列酮抑制A549细胞增殖的IC50（约为80 umol/L）相符。结论 马来酸罗格列酮能够抑制A549细胞中PGC-1a的表达与活性,进而降低细胞中的线粒体质量。这有可能是罗格列酮抑制A549细胞增殖的原因之一。     

氯化锂对兔骨髓间充质干细胞增殖影响

目的研究Wnt/β-catenin通路激活剂氯化锂（LiCl）对兔骨髓间充质干细胞（bone marrowmesen-chymal stem cells,BMSCs）增殖的影响。方法体外纯化培养兔BMSCs,流式细胞仪检测细胞表面抗体,以不同浓度的LiCl作用兔骨髓间充质干细胞24h后,采用Cell Counting Kit-8（CCK-8）检测各组细胞的增殖活性。结果低浓度LiCl促进兔BMSCs增殖,高浓度LiCl抑制兔BMSCs增殖。结论低浓度LiCl抑制GSK3β,模拟激活Wnt/β-catenin信号途径,从而促进细胞增殖,而高浓度LiCl增加了对细胞的毒性而抑制其增殖。     

Advanced glycation end-product-inhibited cell proliferation and protein expression of beta-catenin and cyclin D1 are dependent on glycogen synthase kinase 3beta in LLC-PK1 cells

Glycogen synthase kinase 3β (GSK3β) is increased by high glucose in mesangial cells. Thus, we studied the role of GSK3β in advanced glycation end-product (AGE)-induced effects in the proximal tubule-like LLC-PK1 cells. We found that AGE (100 μg/ml) time-dependently (8-48 h) increased phospho-GSK3β-Tyr216 (active GSK3β) and time-dependently (4-24 h) decreased phospho-GSK3β-Ser21/9 (inactive GSK3β) protein expression. Meanwhile, AGE (100 μg/ml) activated GSK3β kinase at 8-48 h. AGE (100 μg/ml) dose-dependently (75-100 μg/ml) decreased β-catenin protein expression but AGE did not decrease β-catenin protein expression until 48 h. SB216763 (a GSK3β inhibitor) and GSK3β shRNA attenuated AGE (100 μg/ml)-inhibited cell proliferation and protein expression of β-catenin and cyclin D1 at 48 h. SB216763 also attenuated AGE-induced type IV collagen. We conclude that AGE activates GSK3β in LLC-PK1 cells. AGE-inhibited β-catenin and cyclin D1 protein expression are dependent on GSK3β. Moreover, AGE-inhibited cell proliferation and AGE-induced type IV collagen protein expression are dependent on GSK3β.     

Wnt/β-catenin signaling regulates cancer stem cells in lung cancer A549 cells

Wnt/β-catenin signaling plays an important role not only in cancer, but also in cancer stem cells. In this study, we found that β-catenin and OCT-4 was highly expressed in cisplatin (DDP) selected A549 cells. Stimulating A549 cells with lithium chloride (LiCl) resulted in accumulation of β-catenin and up-regulation of a typical Wnt target gene cyclin D1. This stimulation also significantly enhanced proliferation, clone formation, migration and drug resistance abilities in A549 cells. Moreover, the up-regulation of OCT-4, a stem cell marker, was observed through real-time PCR and Western blotting. In a reverse approach, we inhibited Wnt signaling by knocking down the expression of β-catenin using RNA interference technology. This inhibition resulted in down-regulation of the Wnt target gene cyclin D1 as well as the proliferation, clone formation, migration and drug resistance abilities. Meanwhile, the expression of OCT-4 was reduced after the inhibition of Wnt/β-catenin signaling. Taken together, our study provides strong evidence that canonical Wnt signaling plays an important role in lung cancer stem cell properties, and it also regulates OCT-4, a lung cancer stem cell marker.     

锂和三尖杉酯碱对HL—60细胞增殖,分化和c—myc表达的影响

本研究利用细胞培养技术观察了氯化锂和三尖杉酯碱（ＨＴ）对ＨＬ－６０细胞增殖的影响,不同浓度的氯化锂对ＨＬ－６０细胞的集落形成和３Ｈ－ＴｄＲ参入均呈剂量依赖式抑制;三尖杉酯碱亦有类似的作用。在培养体系中加氯化锂和三尖杉酯碱时,对ＨＬ－６０细胞数及集落形成抑制作用与单用二者相比较有明显增加。用ＮＢＴ还原试验,氯化锂和三尖杉酯碱均促进ＨＬ－６０细胞的分化,小剂量氯化锂还能加强三尖杉酯碱对ＨＬ－６０细胞诱导分化作用。从氯化锂和三尖杉酯碱处理的ＨＬ－６０细胞中提取总ＲＮＡ,应用ＲＴ／ＰＣＲ检测ｃ－ｍｙｃ的表达,结果表明经氯化锂和三尖杉酯碱处理的ＨＬ－６０细胞ｃ－ｍｙｃ表达均降低,与未处理的ＨＬ－６０细胞ｃ－ｍｙｃ比较,说明氯化锂和三尖杉酯碱均能抑制ｃ－ｍｙｃ的表达,提示ｃ－ｍｙｃ很可能在白血病细胞增殖、分化中起调控作用。     

CG0009, a Novel Glycogen Synthase Kinase 3 Inhibitor,Induces Cell Death through Cyclin D1 Depletion in Breast Cancer Cells

Glycogen synthase kinase 3α/β (GSK3α/β) is a constitutively active serine/threonine kinase involved in multiple physiological processes, such as protein synthesis, stem cell maintenance and apoptosis, and acts as a key suppressor of the Wnt-β-catenin pathway. In the present study, we examined the therapeutic potential of a novel GSK3 inhibitor, CG0009, in the breast cancer cell lines, BT549, HS578T, MDA-MB-231, NCI/ADR-RES, T47D, MCF7 and MDA-MB-435, from the NCI-60 cancer cell line panel. Assessment of cytotoxicity, apoptosis and changes in estrogen-signaling proteins was performed using cell viability assays, Western blotting and quantitative real-time PCR. CG0009 enhanced the inactivating phosphorylation of GSK3α at Ser21 and GSK3β at Ser9 and simultaneously decreased activating phosphorylation of GSK3β at Tyr216, and induced caspase-dependent apoptosis independently of estrogen receptor α (ERα) expression status, which was not observed with the other GSK3 inhibitors examined, including SB216763, kenpaullone and LiCl. CG0009 treatment (1 µmol/L) completely ablated cyclin D1 expression in a time-dependent manner in all the cell lines examined, except T47D. CG0009 alone significantly activated p53, leading to relocation of p53 and Bax to the mitochondria. GSK3 inhibition by CG0009 led to slight upregulation of the β-catenin target genes, c-Jun and c-Myc, but not cyclin D1, indicating that CG0009-mediated cyclin D1 depletion overwhelms the pro-survival signal of β-catenin, resulting in cell death. Our findings suggest that the novel GSK3 inhibitor, CG0009, inhibits breast cancer cell growth through cyclin D1 depletion and p53 activation, and may thus offer an innovative therapeutic approach for breast cancers resistant to hormone-based therapy.